CHAMP: Children Who Are Nearsighted
Children ages 3 to ≤ 17 who are nearsighted are needed for a 4 year study to determine if a daily investigational eye drop slows the progression of nearsightedness (myopia). Children are randomly assigned to study drug treatment or placebo eye drops; any child assigned to placebo drops during the first 3 years will receive study drug treatment drops in the final year of the study. Participants will complete visits for follow-up (every 6 months) and to pick up study eye drops (every 3 months). Participants receive study related eye care and drops at no cost as well as a yearly allowance towards eyeglasses/contact lenses and reimbursement for travel expenses. For more information, please contact Karen Pollack at 215-276-6053 or email at email@example.com.
Efficacy of Intermittent Occlusion in Amblyopia Treatment
Dr. Jingyun Wang, was funded by the National Eye Institute (NEI). Her grant is entitled “Efficacy of Intermittent Occlusion in Amblyopia Treatment” and it is a 2-year grant funded though the R21 mechanism. The R21 mechanism program supports the early and conceptual stages of research and provides up to two years of funding. Dr. Wang’s study is designed to evaluate the effectiveness of a novel amblyopia treatment - Intermittent occlusion therapy (IO-therapy) using glasses (AmblyzTM) in treating severe amblyopia. Children ages 3 to 8 years with severe amblyopia (visual acuity of 20/100 to 20/400 in the amblyopic eye) will be enrolled and randomized into two groups: 1) standard 6-hour patching group or 2) 12-hour IO-therapy glasses group.
Convergence Insufficiency Attention & Reading Trial (CITT-ART)
The CITT-ART was designed to find out whether therapy for CI improves reading and attention. Children with CI have many more symptoms when reading and show worse attention than children without CI.
We know that CI therapy improves these symptoms and we have some early evidence that treatment also results in improvements in reading and attention. However, to know for sure we need to study this question in a largergroup of children and some children need to receive a harmless control therapy that is not designed to treat convergence insufficiency.
This study is being conducted at 8 sites across the United States and is funded by the National Eye Institute, which is a part of the National Institutes of Health. About 324 children will take part in the study.
CITT-ART Pre-Screening Survey
Binocular Computer Activities Treatment for Amblyopia (ATS 18)
The study is being conducted by the Pediatric Eye Disease Investigator Group (PEDIG). Salus University is a member of this group. The study will include over 500 children at pediatric eye centers across North America and Europe. The National Eye Institute is providing the funding for the study.
Amblyopia is the most common cause of monocular visual impairment in children. The most common way of treating amblyopia is by patching the good eye. Recently, a new way of treating amblyopia has been developed. It involves using both eyes together (binocularly) to play a falling-blocks game on an iPad®. Some initial studies have shown that this new treatment may work well in some children and adults. We are conducting a clinical trial to evaluate the effectiveness of one hour/day of daily binocular iPad treatment compared with two hours/day of daily patching treatment.
Currently, we are recruiting children with amblyopia who are 5 to less than 17 years old.
For more Information contact:
- Visual acuity in the amblyopic eye between 20/40 and 20/200
- Random assignment to either:
- 1 hour/day of binocular iPad treatment, 7 days per week, OR
- 2 hours of daily patching treatment, 7 days per week
- Follow-up visits at 4, 8, 12 and 16 weeks
- At the end of the study (after 16 weeks of treatment), children who are randomly assigned to patching will be offered the opportunity to try the binocular iPad treatment for 16 weeks (outside of the study).
Karen Pollack, Study Coordinator at:
ATS 18 Brochure